Table 3

Symptoms, medication and C reactive protein levels of study patients

Exacerbated COPDStable COPDp value
Data are median (range) or absolute numbers and percentages as indicated. Probability according to Mann-Whitney U tests. p<0.05 is considered to be statistically significant.
Wheezing/rhonchi (n, %)76/85 (89.4%)22/42 (52.4%)<0.01
Nasal congestion (n, %)42/85 (49.4%)9/42 (21.4%)<0.01
Rhinorrhea (n, %)33/85 (38.8%)10/42 (23.8%)0.04
Sore throat (n, %)19/85 (22.4%)1/42 (2.4%)0.01
Purulent sputum (n, %)49/85 (57.6%)14/42 (33.3%)0.02
Fever (n, %)14/85 (16.5%)0/42 (0%)0.01
Headache (n, %)27/85 (31.8%)4/42 (9.5%)0.01
Muscle pain (n, %)16/85 (18.8%)1/42 (2.4%)0.02
Hoarseness (n. %)34/85 (40.0%)13/42 (31%)0.43
Exacerbations in the preceding year (n, range)2 (0–12)1 (0–8)0.03
Oral steroids before admission (n, %)49/85 (57.7%)23/42 (54.8%)0.91
Oral steroids before admission (mg/day)5 (0–80)5 (0–150)0.88
C-reactive protein (mg/dl)1 (0–31)0 (0–8.2)<0.01